SURMOUNT-1: Tirzepatide Achieves 22.5% Weight Reduction in 72 Weeks

In July 2022, the New England Journal of Medicine published SURMOUNT-1 — a landmark Phase 3 trial of tirzepatide in adults with obesity. At the highest dose of 15 mg once-weekly, participants lost an average of 22.5% of body weight (approximately 24 kg / 52 lbs) over 72 weeks. At the time of publication, this was the largest weight reduction ever demonstrated by a pharmacological agent.

The Trial

2,539 adults with a BMI ≥30 (or ≥27 with at least one weight-related condition, but without type 2 diabetes) were randomised to tirzepatide at 5 mg, 10 mg, or 15 mg once weekly, or placebo, for 72 weeks. The study was double-blind and placebo-controlled.

Key Results

At the 15 mg dose:

• 22.5% mean body weight reduction from baseline
• Mean weight loss of approximately 24 kg (52 lbs)
• 91% of participants lost at least 5% of body weight vs. 35% on placebo
• 57% lost at least 20% of body weight — a magnitude previously only seen with bariatric surgery

At 10 mg, mean weight loss was 19.5%. At 5 mg, it was 15.0% — all statistically significant vs. placebo.

"Tirzepatide produced sustained, clinically meaningful reductions in body weight that were greater than those seen with any approved anti-obesity medication." — Jastreboff et al., NEJM 2022

Dual Receptor Mechanism

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind approved for obesity. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation enhances the metabolic effect and appears to improve the tolerability of the GLP-1 component. The combination achieves greater fat loss than GLP-1 alone.

Safety

Nausea, diarrhoea, and vomiting were the most common adverse events, predominantly mild-to-moderate and highest during dose escalation. Serious adverse events occurred in 6.3% of the tirzepatide group vs. 4.3% placebo — a difference driven partly by cholelithiasis (gallstones), a known consequence of rapid weight loss rather than a direct drug effect.

Why This Matters

SURMOUNT-1 demonstrated that dual-receptor agonism meaningfully outperforms single-receptor GLP-1 therapy. The 22.5% result at 15 mg represented a step-change from semaglutide's 14.9% in STEP-1, validating the hypothesis that targeting multiple metabolic pathways produces compounding benefits.